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1. Introduction
Feline immunodeﬁciency virus (FIV) is an important
pathogen of domestic cats that is distributed worldwide.
Prevalence estimates vary from 1% to 44%, depending on
the geographical location as well as the entry criteria of
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A B S T R A C T
Despite over 25 years of feline immunodeﬁciency virus (FIV) research, relatively little is
known about the longitudinal course of FIV infection following natural infection. In
contrast to published reports of experimental infections using lethal strains of the virus,
clinical signs of naturally acquired FIV infection can be mild or inapparent, rather than life-
threatening. In this prospective, longitudinal controlled study, based in Chicago, IL (n = 17)
and Memphis, TN (n = 27), we investigated two cohorts of privately owned, naturally
infected cats kept under different housing conditions. Cats in the Chicago cohort (Group 1)
were kept in households of 2 cats, while the Memphis cohort (Group 2) comprised part of
a large multi-cat household of over 60 cats kept indoors only, with unrestricted access to
one another.
The majority of cats from Group 1 did not display clinical signs consistent with
immunodeﬁciency during the 22-month observation period. In contrast, the outcome of
infection in Group 2 was dramatically different; 17/27 (63%) of cats lost a median of 51.3%
of their bodyweight (P < 0.0005) and died during the study period, with lymphoma being
the most common cause of mortality.
Although the decrease in CD4+ T cell count between enrolment and terminal disease
was signiﬁcant (P = 0.0017), the CD4:CD8 ratio at the time of enrolment did not reliably
distinguish FIV-positive cats classiﬁed as ‘healthy’ and ‘not healthy’ at either cohort. FIV
load at enrolment was signiﬁcantly lower in Group 1 than in Group 2 (P < 0.0001), but
there were no signiﬁcant differences at enrolment between healthy and not healthy cats at
either group.
In conclusion, the results of this study suggest that management and housing
conditions impact on disease progression and survival times of FIV-positive cats.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).
 Corresponding author at: MRC Centre for Virus Research, University
Glasgow, Glasgow, UK. Tel.: +44 141 330 6068.
E-mail address: pawel.beczkowski@glasgow.ac.uk (P.M. Be˛czkowski).
Contents lists available at ScienceDirect
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dult, male, sick cats with bite wounds are at increased risk
f infection, since transmission is mainly via bites from
fected cats (Hartmann, 1998). Clinical signs are similar to
ose described for human immunodeﬁciency virus-
cquired immune deﬁciency syndrome (HIV-AIDS) and
clude signs of immunosuppression, hematopoietic
hanges and neoplasia (Hartmann, 2011). The progression
f experimental FIV infection can be monitored using the
taging system used in HIV infection: acute, persistent
eneralized lymphadenopathy, asymptomatic carrier
hase (AC), AIDS-related complex (ARC) and AIDS (English
t al., 1994). While this classiﬁcation is useful in well-
ontrolled, experimental settings, it has limitations under
eld conditions, mainly because of strain-related variabil-
y in pathogenicity, variation in the ages of cats at the time
f infection as well as possible exposure to secondary
athogens (Hartmann, 2012; Pedersen et al., 2001; Podell
t al., 1997). Hence, there have been variable morbidity
nd mortality rates reported in naturally infected cats
ddie et al., 2000; Hofmann-Lehmann et al., 1997;
ohmoto et al., 1998; Liem et al., 2013).
Providing an accurate prognosis for FIV-positive cats is
portant so that optimal care can be provided by
eterinarians and cat owners. Surrogate markers for HIV
fection are well established and valuable in monitoring
oth responses to therapy and the likelihood of disease
rogression (Churchill, 1997; Katzenstein, 2003; Okonji
t al., 2012; Shaunak and Teo, 2003; Smith and Stein,
002). In contrast, to our knowledge, prospective con-
olled studies investigating the course of FIV infection and
arkers of disease progression have not been described.
onsequently, the longitudinal course of naturally ac-
uired FIV infection is poorly described and the variability
 rates of progression to immunodeﬁciency are poorly
nderstood.
In this controlled study, we examined clinical and
boratory parameters from two cohorts of cats living in
ifferent locations and kept under different housing
onditions. The aim of the study was to report clinical
ndings, post-mortem ﬁndings, bodyweight, CD4+ T cell
ounts, FIV load and phylogenetic classiﬁcation of viral
nvelope genes in two groups of cats naturally infected
ith FIV.
. Materials and methods
.1. Cats
Forty-four neutered, FIV-positive (SNAP FIV/FeLV Com-
o Test (IDEXX Laboratories, Westbrook, MN) cats were
nrolled, with an equal number of age- and sex-matched
IV-negative cats from the same geographical locations. In
rder to obtain an adequate sample size FIV-positive cats
nd matched control cats during the 2-year enrolment
eriod, it was necessary to source cats from two separate
cations. FIV-positive results were further conﬁrmed by
irus isolation (Hosie et al., 2009). All cats were feline
ukaemia virus (FeLV) antigen negative at enrolment. The
umber of cats enrolled into the study was capped at 44
due to the capacity of the laboratory at which molecular
analyses were performed.
Seventeen of the 44 FIV-positive cats enrolled (Group 1)
had been previously adopted from a large metropolitan
adoption-guarantee shelter (PAWS Chicago) and lived in
single-cat households in Chicago, IL, USA except for seven
cats: two cats (C7 and C4) cohabited in a two-cat
household; one cat (C13) lived in a two-cat household
with a FIV-negative cat enrolled in the study; one cat (C9)
was housed at PAWS Chicago for the ﬁrst 11 weeks of the
study and then was adopted into a house with an FIV-
positive cat not enrolled in the study; and three cats (C2,
C15 and C21) were housed at PAWS Chicago in a room
containing up to three FIV-positive cats before they were
each adopted into single cat households at 2, 14 and 58
weeks after enrolment, respectively.
The remaining twenty-seven FIV-positive cats en-
rolled (Group 2) were housed together in a large multi-
cat household operating as an FIV-positive cat rescue in
Memphis, TN, where a total of 53 FIV-positive and 10
FIV-negative cats were housed indoors with unrestrict-
ed access to one another. None of 10 FIV-negative cats
from the Memphis cat rescue died during the study
period. Since these cats were not age- or sex-matched for
any of the enrolled FIV-infected cats from the same
household (Group 2), their health status was not
monitored using the study protocol. All enrolled FIV-
negative cats at both locations lived in households of
three cats or fewer.
The study and its aims were reviewed and approved by
University of Glasgow Ethics Committee and the Purdue
Animal Care and Use Committee. Cat owners provided
written informed consent for their participation in the
study.
2.2. Study timeline and collection dates
At enrolment, all cats underwent a general physical
examination by a registered specialist in feline medicine
(AL) and blood was collected for determination of FIV
status and laboratory analysis. Oral examinations were
conducted as part of the physical examination and a
gingival score (0–3/3; Lobprise, 2007) was assigned. At the
time of enrolment, FIV-positive cats were classiﬁed as
‘healthy’ if there were no abnormalities on physical
examination and their gingival score was 0/3 or 1/3. Cats
were classiﬁed as ‘not healthy’ if at least one clinical
abnormality was detected, or if their gingival score was 2/3
or 3/3. The clinical classiﬁcation at enrolment was based
solely on physical examination ﬁndings and remained
with each cat for the 22-month study period, regardless of
any further changes. An entry criterion for age- and sex-
matched FIV-negative cats was healthy status at the
enrolment examination.
Serial physical examinations and specimen collections
were made at 6-monthly intervals in FIV-positive cats over the
study period. Physical examinations and specimen collections
were performed at enrolment and 12 months later in FIV-
negative cats. The date of the ﬁrst known positive FIV ELISA
test was obtained for all FIV-positive cats and the time
between ﬁrst diagnosis and study enrolment (months) was
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P.M. Be˛czkowski et al. / Veterinary Microbiology 176 (2015) 50–6052lculated. Abnormalities detected during the clinical exam-
ations are listed in Table 1.
. Laboratory and post-mortem examinations
Flow cytometric analyses were performed as previously
scribed (Lin and Litster, 2013). FIV loads were measured
ing a commercially available PCR test (IDEXX FIV
alPCR Test, IDEXX Laboratories, West Sacramento, CA).
e assay detects the presence of viral nucleic acid,
cluding both genomic DNA and viral RNA, in peripheral
ood leukocytes with 80.5% sensitivity and 99.9% speci-
ity (IDEXX Laboratories, West Sacramento, CA).
Post-mortem examinations were performed by a
ecialist veterinary pathologist (TLL).
. Phylogenetic analysis
Maximum likelihood (ML) phylogenetic trees were
nstructed in MEGA5 (Tamura et al., 2011) under the HKY
cleotide substitution model, selected through jMO-
LTEST (Posada, 2008). Statistical support for the ML
es was estimated using 1000 bootstrap replicates (Efron
 al., 1996). Multiple env sequences (n = 355), from cats
rolled in the study were subjected to rigorous recombi-
tion testing as described previously (Be˛czkowski et al.,
14).
. Statistical analysis
Graphing and statistical data analyses were performed
ing commercially available software (GraphPad Prism
rsion 5.00, GraphPad Software). Descriptive data were
own as medians and interquartile range (IQR; median,
h and 95th quartiles). Given the relatively small sample
e, and after inspection of the data distributions, Mann–
hitney and Wilcoxon matched pairs tests were used to
st hypotheses regarding differences in laboratory pa-
meters between and within cat groups. Binary data were
alyzed using Fisher’s exact test. FIV load data were
sted for correlation using Spearman correlation tests.
plan–Meier curves were compared using the Mantel–
x ‘log-rank’ test and tested with the log-rank test for
nds. Signiﬁcance was set at P < 0.05.
3. Results
3.1. Cats
Table 2 provides breed, gender, age and time since ﬁrst
FIV-positive test data for all FIV-positive cats and for cats
from Group 1 and Group 2. Each matching pair of FIV-
positive and FIV-negative cats was aged within 2 years of
each other. All enrolled cats remained FeLV-negative over
the study period and none of the FIV-negative cats
seroconverted.
3.2. Health status
In the FIV-positive group at the time of enrolment, there
were equal numbers of healthy (n = 22) and not healthy
animals (n = 22). In Group 1, 10 cats were classiﬁed as
healthy (59%) and seven cats were classiﬁed as not healthy
(41%); all but one cat remained in this classiﬁcation during
the observation period. In Group 2, 12 cats were initially
classiﬁed as healthy (44%) and 15 cats that were classiﬁed as
not healthy (56%) remained in these classiﬁcations through-
out the study. However, 63% of cats (17/27) from Group 2
experienced severe weight loss and died during the study
period. Half (6/12) of the cats classiﬁed as healthy and 73%
(11/15) of cats classiﬁed as not healthy died during the
study (P = 0.26). Almost half of cats diagnosed at post-
mortem with lymphoma (44%; 4/9) had been classiﬁed as
healthy at the time of enrolment (Table 3).
3.3. Post-mortem ﬁndings
During the 22-month study period, 1/17 (5.9%) FIV-
positive cats from Group 1 and 17/27 (63%) FIV-positive
cats from Group 2 died. Fig. 1 illustrates a Kaplan–Meier
survival plot of both cohorts. The cats that died were
examined post-mortem and the ﬁndings are shown in
Table 3. In Group 2, post-mortem data were not available
for one cat (M33).
The most common pathological ﬁnding at post-mortem
in Group 2 was lymphoma; various anatomical types were
documented in 9/16 (56%) cats from Group 2 (Table 4).
Four cats had lymphoma limited to a single site (retro-
bulbar site in one case and bone marrow in three cases),
while in ﬁve other cats, varying degrees of dissemination
ble 1
nical abnormalities detected on physical examination in FIV-positive cats (n = 44) over the 22-month study period.
escription Number of cats with clinical abnormalities (%)
Group 1 (n = 17) Group 2 (n = 27) All FIV-positive cats (n = 44)
ental/oral cavity (faucitis) 12 (71) 19 (70) 31 (70)
kin (alopecia, dermatitis) 10 (59) 12 (44) 22 (50)
ars 3 (18) 4 (15) 7 (16)
cular disease 2 (12) 5 (19) 7 (16)
ardiovascular 3 (18) 2 (7) 5 (11)
igestive tract 0 (0) 4 (15) 4 (9)
espiratory 0 (0) 2 (7) 2 (5)
ymph nodes 0 (0) 0 (0) 0 (0)
rogenital 0 (0) 0 (0) 0 (0)
eurologic 0 (0) 0 (0) 0 (0)
usculoskeletal 0 (0) 0 (0) 0 (0)eight loss/anorexia 0 (0) 22 (81) 22 (50)
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P.M. Be˛czkowski et al. / Veterinary Microbiology 176 (2015) 50–60 53ere observed. Bone marrow involvement was noted in
ll but one case. The second most common ﬁnding was
odal lymphoma, diagnosed in 5/9 cats (56%) and
ccompanied by splenic lymphoma in 3/9 cases (33%).
ne cat (M11) had a disseminated form involving the
idneys, liver, jejunum, heart, trachea and tongue. The
edian time since ﬁrst FIV-positive ELISA test to death
 cats with lymphoma was 5.3 years (range, 2.9–9
ears).
Lymphoid hyperplasia and lymphoid depletion were
oted concurrently in 13/16 (81%) cats. These ﬁndings
ere documented in various tissues, mostly in the spleen
nd lymph nodes, but in four cats, Peyer’s patch atrophy
as also diagnosed. Erythroid bone marrow hyperplasia
as documented in 9/16 cats (56%), as was myeloid bone
arrow hyperplasia. Multifocal lymphocytic interstitial
ephritis was diagnosed in six cats (37.5%). In four cats,
ere were pathological signs of respiratory tract infection
nd pneumonia. Hypertrophic cardiomyopathy and signs
f congestive heart failure were identiﬁed in the single
IV-positive cat from Group 1 that died.
None of the FIV-negative cats died during the study
period.
3.4. Bodyweight
The bodyweight at the time of death for the single FIV-
positive cat from Group 1 cohort that died was 15% heavier
than the bodyweight recorded at enrolment (Fig. 2). The 17
FIV-positive cats from Group 2 that died lost a median of
51.3% of their bodyweight between enrolment (median
3.9 kg, range 2.27–5.54 kg) and death (median 1.9 kg,
range 1.45–3.72 kg; P < 0.0005), over a median time span
of 15 months (range 1.6–20 months). Those cats lost a
median of 10.9% of their bodyweight between enrolment
and 3 months before death (range 26.3% to +9.3%);
median bodyweight loss in the last 3 months of life was
29.5% (range 55.4% to 8.9%).
The 16 FIV-positive cats from Group 1 that survived for
the entire study period gained a median of 7.6% bodyweight
over the 12 months following enrolment (enrolment,
median 5.9 kg, range 3.8–8.4 kg; 12 months later 6.35 kg,
able 2
reed, gender, age and age at ﬁrst known positive feline immunodeﬁciency virus (FIV) ELISA test at enrolment.
Group 1 (n = 17) Group 2 (n = 27) All FIV-positive cats (n = 44)
Breed DSH (94%), DLH (6%) DSH (74%), DLH (15%), Siamese X (11%) DSH (82%), DLH (11%), Siamese X (7%)
Gender FS (18%), MN (82%) FS (33.3%), MN (66.6%) FS (27%), MN (73%)
Age (years; median/range) 4/1–9 5/2–10 4.5/1–10
Age at ﬁrst known positive
FIV ELISA test (years;
median/range)
2.3/0.2–7.8 1.6/0–4.6 1.8/0–7.8
Time from ﬁrst known
positive FIV ELISA test
to enrolment (years;
median/range)
1.3/0–3.3 3/0.1–8 2/0–8
SH, domestic shorthair; DLH, domestic longhair; X, cross; FS, female spayed; MN, male neutered.
able 3
ealth status on the day of enrolment and post-mortem diagnoses for FIV-positive cats deceased during the study (Group 1, n = 1; Group 2, n = 17).
Cat # Health status at enrolment Post-mortem diagnosis
M3 NH Lymphoma – retrobulbar
M5 NH Lymphoma – bone marrow
M10 H Lymphoma – bone marrow and lymph nodes
M11 H Lymphoma – multicentric
M14 NH Lymphadenomegaly; bone marrow hyperplasia
M16 NH Pulmonary congestion and oedema with focal bacterial bronchopneumonia
M25 H Upper and lower bacterial respiratory infection, probably secondary to viral infection
M26 NH Chronic focal granulomatous nematode larval pneumonia; bone marrow hyperplasia
M30 NH Lymphoid depletion; Aelurostrongylus abstrusus pneumonia; left front leg suppurative
dermocellulitis; bone marrow hyperplasia, with erythroid and myeloid hyperplasia
M31 NH Lymphoma – bone marrow
M33 NH No post-mortem performed
M41 NH Lymphoma – bone marrow and lymph nodes
M44 NH Emaciation/nephritis/pancreatitis
M46 H Lymphoma – bone marrow
M48 NH Lymphoma – bone marrow and lymph nodes
M49 H Lymphoma – bone marrow
M50 H Undetermined/emaciation
C2 H Cardiac failure, hypertrophic cardiomyopathy, Chicago, Group 1; M, Memphis, Group 2; H, healthy on the day of enrolment (no abnormalities detected on a physical examination); NH, not healthy on
e day of enrolment (at least one abnormality detected on a physical examination).
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P.M. Be˛czkowski et al. / Veterinary Microbiology 176 (2015) 50–6054nge 3.9–8.1 kg; P = 0.2089). In contrast, the 10 FIV positive
ts from Group 2 that remained alive lost a median
 12.8% of their bodyweight over the 12 months
llowing enrolment (enrolment, median 4.68 kg, range
34–7.67 kg; 12 months later, median 4.08 kg, range
45–7.89 kg; P = 0.2324).
FIV-negative cats from Group 1 for which bodyweight
ta were available (n = 16) gained a median 16.8%
dyweight between enrolment (median 5.35 kg, range
8.5 kg) and 12 months later (median 6.25 kg, range
1–8 kg; P = 0.0145). Similarly, FIV negative cats from
emphis for which bodyweight data were available
 = 24) gained a median of 24.5% bodyweight between
rolment (median, 4.9 kg, range 2.7–9 kg) and 12
onths later (median 6.1 kg, range 2.6–9.9 kg;
 0.0022).
Available bodyweight data from Group 2 demonstrated
at enrolment weights for FIV-positive cats from Group 2
at died were signiﬁcantly lower than those for matched
-negative cats (n = 17; FIV-positive, median 3.9 kg,
nge 2.27–5.54; FIV-negative, median 5.6 kg, range 2.7–
 kg; P = 0.0046). Bodyweights were not statistically
fferent when FIV-positive survivors from Group 2 and
atching FIV-negative cats were compared at enrolment
 = 10; FIV-positive, median 5.12 kg, range 3.34–7.68 kg;
-negative median 5.8 kg, range 4.6–9.0 kg; P = 0.1641)
d 12 months later (FIV-positive, median 4.63 kg,
nge 3.63–8.27 kg; FIV-negative, median 6.2 kg, range
–9.9 kg; P = 0.0977).
3.5. CD4+ T cell counts and CD4:CD8 ratio
Fig. 3 illustrates the CD4:CD8 ratios obtained over 12
months for the FIV-positive cats from Group 2 with
reference values acquired from FIV-negative cats classiﬁed
as healthy from the same geographic location. The differ-
ence between FIV-positive (median 0.89, range 0.19–2.24)
and FIV-negative cats (median 1.71, range 1.03–2.62) was
statistically signiﬁcant at the time of enrolment (P < 0.0001)
and 12 months later (medians 0.69, range 0.11–1.54 and
1.48, range 0.88–2.77 for FIV-positive and FIV-negative cats,
respectively; P < 0.0001). The CD4:CD8 ratio in surviving
FIV-positive cats was maintained over 18 months at a
consistently low level (median values: 0.89, 0.73, 0.69, and
0.81 for each time point).
CD4:CD8 ratio at the time of enrolment (P < 0.0005)
was lower in the FIV-positive cats from Group 1 (median
0.77, range 0.08–1.27) than in matched FIV-negative cats
(median 2.18, range 1.23–6.42; Fig. 3). CD4:CD8 ratios in
the FIV-positive cats from Group 1 were maintained at a
consistently low level over the 12 months following
enrolment (median 0.65, range 0.2–2.55) compared to
age- and sex-matched FIV-negative cats (median 1.8,
range 1.4–3.93; P = 0.0054). The CD4:CD8 ratios at the
time of enrolment in the FIV-positive cats from Group 1
were lower (median 0.77, range 0.08–1.27) than those of
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. 1. Kaplan–Meier survival plots for FIV-positive cats from Group 1
ack; n = 17) and Group 2 (red; n = 27). Survival rates in Group 1 and
oup 2 over the 22-month study period were 94% and 37%, respectively
= 0.0006, Gehan–Breslow–Wilcoxon test). (For interpretation of the
erences to colour in this ﬁgure legend, the reader is referred to the web
rsion of this article.)
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Fig. 2. Bodyweights of FIV-positive cats from Group 1 (n = 17) and Group 2
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study period; White boxes denote cats dead at the end of the 22-month
study period. (The central bar in the box denotes the median, while the
top and bottom of the box represent the 75th and 25th centiles,
respectively. The upper and lower bars represent the 95th and 5th
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P.M. Be˛czkowski et al. / Veterinary Microbiology 176 (2015) 50–60 55he FIV-positive cats from Group 2 (median 0.89, range
.19–2.23; Fig. 3).
There were no statistically signiﬁcant differences when
e CD4:CD8 ratio was compared between cats classiﬁed
s healthy and not healthy at enrolment at either group, or
r all FIV-positive cats as a single group (Group 1, P = 0.97;
roup 2, P = 0.84; all FIV-positive cats, P = 0.99; Fig. 4).
To determine the kinetics of the CD4:CD8 ratio
version over the course of infection, we compared
bsolute CD4+ and CD8+ T lymphocyte numbers from
7 cats from Group 2 that died during the study (Fig. 5).
he decrease in CD4+ T cell count was statistically
igniﬁcant when enrolment results (median 0.41 K/mL,
ange 0.13–1.38 K/mL) were compared with terminal
esults (median 0.18 K/mL, range 0.04–1.32 K/mL;
 = 0.0017), but this was not the case for the decrease in
CD8+ T cell count from enrolment (median 0.44 K/mL, range
0.18–1.49 K/mL) to terminal disease (median 0.38 K/mL,
range 0.06–1.68 K/mL; P = 0.35). Therefore, the decrease in
the CD4:CD8 ratio was attributed to a reduction in the
CD4+ T cell count. Further analysis of total lymphocyte
counts in deceased cats showed that the decrease in
absolute lymphocyte numbers between enrolment (me-
dian 1.73 K/mL, range 1.15–4.03 K/mL) and terminal
disease (median 1.25 K/mL, range 0.25–3.55 K/mL)
reﬂected not only the loss of CD4+ T cells, but also
depletion of CD21+ B cells (enrolment, median CD21+ B
cell count 0.26 K/mL, range 0.12–0.89 K/mL; terminal
specimens, median CD21+ B cell count 0.17 K/mL, range
0.04–0.37 K/mL; P = 0.0061).
3.6. FIV load (FIV genomes/mL blood)
The FIV load at enrolment was signiﬁcantly lower in
Group 1 (median, 741 genomes/mL blood; range 43–
18,796 genomes/mL blood) than Group 2 (median, 50,003
genomes/mL blood; range, 2540–3,792,000 genomes/mL
blood; P < 0.0001; Fig. 6). There were no statistically
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Fig. 6. FIV load at the time of enrolment (genomes/mL blood). Statistical
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G1, Group 1 (n = 15); G2, Group 2 (n = 26); H, healthy on the day of
enrolment (no abnormalities detected on a physical examination; Group
1, n = 8, Group 2, n = 11); NH, not healthy on the day of enrolment (at least
one abnormality detected on a physical examination; Group 1, n = 7,
Group 2, n = 15); A, alive at the end of the 22-month study period (Groupe 75th and 25th centiles, respectively. The upper and lower bars
present the 95th and 5th centiles, respectively.)
2, n = 9); D, cats dead at the end of the 22-month study period (Group 2,
n = 17). ***P < 0.0001.
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althy and not healthy cats were compared in Group 1
ealthy, n = 8, median 717 genomes/mL blood; range,
–18,796 genomes/mL blood; not healthy, n = 7, median
7 genomes/mL blood; range, 395–18,796 genomes/mL
ood; P > 0.05) or Group 2 (healthy, n = 11, median 64,843
nomes/mL blood; range, 2540–1,667,000 genomes/mL
ood; not healthy, n = 15, median 41,387 genomes/mL
ood; range, 13,423–3,792,000 genomes/mL blood;
 0.05). In Group 2, there were no signiﬁcant differences
 FIV load at enrolment when the following comparisons
ere made: cats still alive vs. cats that had died by the end
 the study period (alive, n = 9, median 31,395 genomes/
L blood; range, 2540–41,8671 genomes/mL blood; dead,
 17, median 176,551 genomes/mL blood; range, 7724–
92,000 genomes/mL blood; P > 0.05); cats that had died
 the end of the study period and were classiﬁed at
rolment as either healthy or not healthy (healthy, n = 6,
edian 241,757 genomes/mL blood, range, 7724–
67,000 genomes/mL blood; not healthy, n = 11, median
6,551 genomes/mL blood; range, 13,423–3,792,000
nomes/mL blood; P > 0.05); and cats that were still
ve by the end of the study period and were classiﬁed at
rolment as either healthy or not healthy (healthy, n = 5,
edian 56,867 genomes/mL blood, range, 2540–418,671
nomes/mL blood; not healthy, n = 4, median 27,771
nomes/mL blood, range 16,176–43,138 genomes/mL
ood; P > 0.05).
Statistical correlations between FIV load and CD4+ T
lls, CD8+ T cells and the CD4:CD8 ratio were investigated
r each group. There were statistically signiﬁcant, or close
 signiﬁcant, negative correlations between the CD4:CD8
tio and FIV load in Group 1 (r = 0.5022; P = 0.0564) and
 Group 2 (r = 0.5479; P = 0.0038; Fig. 7).
. Phylogenetic classiﬁcation of FIV envelope genes
Full-length viral envelope (env) gene sequences from
-positive cats were examined (n = 355). In Group 1,
de B env viruses and clade A/B recombinant env viruses
ch accounted for 50% of infections. In Group 2, 69% of
ts were infected with viruses bearing clade B env, while
% of cats were infected with recombinant env viruses
upplementary Table 3).
4. Discussion
Here we describe contrasting clinical outcomes of
naturally acquired FIV infection, demonstrating signiﬁcant
differences between cats enrolled from two separate
cohorts. The relationship between FIV infection and
clinical disease is unclear, with some studies reporting
that infected cats are at increased risk of morbidity and
mortality (Muirden, 2002), while others report no such
association (Akhtardanesh et al., 2010; Liem et al., 2013).
Considering all 44 FIV-positive cats, there was no
relationship between mortality and morbidity and FIV
infection; however, this was not the case when the two
cohorts were examined separately. Our observations in
Group 2 indicated that living conditions might have played
a role in the more rapid disease onset. In contrast, cats from
Group 1 were generally housed in single cat households
and remained alive and in relatively good health over the
study period. Therefore, it appears that FIV infection is
more likely to progress in cats kept in crowded shelter
conditions compared to those living in spacious environ-
ments. As a corollary, our results suggest that the FIV-
positive cats in our study that lived in single or dual cat
households remained free of clinical signs of illness over
the study period; this can most likely be attributed to
lower risks of exposure to opportunistic pathogens and
reduced levels of environmental stress.
FIV infected cats are at greater risk of opportunistic
infections and neoplasia (Hartmann, 2012). Regular
assessment of their health status is essential and,
according to European Advisory Board on Cat Diseases
guidelines (Hosie et al., 2009), health checks are recom-
mended every 6 months. The short time to disease
progression leading to the deaths of 63% of cats in Group
2 within the 22-month follow-up period was unexpectedly
high, especially in light of previously published studies
that were unable to demonstrate a difference in lifespan
between FIV-positive and FIV-negative cats (Addie et al.,
2000; Ravi et al., 2010). The health status of cats from
Group 1 was similar to that of cats in a household in which
FIV infection did not reduce life expectancy over a period of
2 years (Addie et al., 2000). There are several clinical
abnormalities associated with FIV infection, with gingi-
vostomatitis being the most common. Although one study
(Quimby et al., 2008) did not observe an association
between FIV infection and gingivostomatitis, the high
prevalence observed here was in agreement with previous
reports (Bandecchi et al., 1992; Hofmann-Lehmann et al.,
1995; Hosie et al., 2009; Knotek et al., 1999). As
gingivostomatitis is rare in SPF cats experimentally
infected with FIV, co-infections with other infectious agents,
such as feline calicivirus, might have contributed to this
syndrome in naturally infected cats (Reubel et al., 1994;
Tenorio et al., 1991). It is perhaps relevant that severe acute
on chronic upper respiratory tract disease was diagnosed in
four cats from Group 2 at post-mortem. Other abnormalities
previously attributed to FIV-induced dysregulation and
impairment of immune surveillance include dermatitis,
ocular disease, renal insufﬁciency, lower urinary tract
infections and other opportunistic infections (Barlough
et al., 1991; Reche et al., 2010). Although neurological
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4:CD8 ratio for FIV-positive cats from Group 1 (n = 15; r = 0.5022,
 0.0564) and Group 2 (n = 26; r = 0.5479, P = 0.0038).
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ental, acute and chronic FIV infections (Abramo et al.,
995; Dow et al., 1990; Podell et al., 1997, 1999), neither
ehavioural nor motor abnormalities were observed in our
tudy population.
The mortality rate of 63% in the FIV-positive cats from
roup 2 was markedly higher than the FIV-positive cats
om Group 1, in which only one cat died during the study
eriod (6%). Post-mortem examinations identiﬁed several
athological changes in the FIV-infected cats. Although FIV
fection is generally associated with immunosuppression,
mune hyperstimulation is evident during the early
tages of infection, including B cell activation, manifested
s polyclonal hypergammaglobulinemia (Hopper et al.,
989; Takano et al., 2012), expansion of CD8+ T cells with
n activated phenotype and subsequent CD8+ T lympho-
ytosis (Beatty et al., 1996; Willett et al., 1993). Lymph
ode follicular hyperplasia and dysplasia was documented
ost-mortem in this study, conﬁrming the ﬁndings of other
tudies of acute and terminal stage disease (Matsumura
t al., 1993; Shelton et al., 1989; Yamamoto et al., 1988). In
ddition, reactive changes in the bone marrow, observed in
6% of cats in this study, have been documented previously
 HIV and FIV infections (Bain et al., 2009; Breuer et al.,
998; Geller et al., 1985).
Lymphoma was the most common condition diagnosed
t post-mortem in Group 2 (9/16 cats; 56%), which raises
uestions regarding potential interactions between virus,
ost, environment, and other factors that could have
esulted in a predisposition to neoplasia. FIV strain
ariability was examined, since the Memphis FIV strains
roup 2) might have had greater oncogenic potential than
e strains infecting the Chicago cohort (Group 1).
owever, a comparison of full-length env gene and long
rminal repeat sequences revealed no signiﬁcant differ-
nces (unpublished observation). It is possible that the local
luster of lymphoma in Group 2 was associated with another
fectious agent, such as FeLV, but this seemed unlikely
ince FIV/FeLV Snap test (IDEXX) results were negative for
eLV antigen. However, we cannot exclude the possibility of
egressive FeLV infection (Hofmann-Lehmann et al., 2001),
ince PCR testing to detect integrated proviral DNA in
one marrow was not performed. Breed was unlikely to
lay a role, as the cats from Group 2 diagnosed with
mphoma and those from Group 1 were all classiﬁed as
omestic shorthairs and came from a variety of sources
ithin their geographic area. The shelter environment in
hich the cats from Group 2 lived was likely to play a role
 the development of the various clinical manifestations
f FIV, although exposure to potential carcinogens cannot
e ruled out.
Marked weight loss between enrolment and terminal
easurement was evident among the cats that died over
e study period, whereas healthy FIV-infected cats
aintained relatively stable bodyweights (Fig. 2). Al-
ough monitoring bodyweight regularly can be a valuable
ol in the care of FIV-positive cats and appeared to have
ome prognostic value in our study of FIV-positive cats,
eclining bodyweight is a relatively non-speciﬁc ﬁnding,
s it is not unusual to observe weight loss during the
rogression of various other diseases.
The hallmark of FIV infection is an inverted CD4:CD8
ratio, which, as demonstrated here and elsewhere (Hoff-
mann-Fezer et al., 1992; Novotney et al., 1990; Tompkins
et al., 1991), is largely the consequence of a loss of CD4+ T
cells. Here we provide further evidence that FIV-positive
cats had signiﬁcantly lower CD4:CD8 ratios than those for
FIV-negative cats over the 22-month study period in each
of the cohorts (Fig. 3). We also observed a statistically
signiﬁcant decline in the CD4:CD8 ratio between the time
of enrolment and the terminal sampling in those cats that
died over the study period (Fig. 5). However, there was not
a signiﬁcant difference in median CD4:CD8 ratio at
enrolment when cats classiﬁed as either healthy or not
healthy were compared (Fig. 4). Both groups of cats had
relatively low CD4:CD8 ratios with median values less
than 1, regardless of their health status. Indeed, the cat
that had the lowest CD4+ T lymphocyte count (0.09 K/mL)
and the lowest CD4:CD8 ratio (0.08) at enrolment was
classiﬁed as healthy and is still alive. Similar observations
have been reported previously in FIV (Novotney et al.,
1990) and HIV infections (Levy, 1988), where seropositive
individuals remained asymptomatic despite signiﬁcant
loss of CD4+ T lymphocytes. The variability in CD4:CD8
ratios among healthy and not healthy cats in this study
population also limited their utility in the prediction of
disease progression.
Extrapolating from HIV infection, the plasma viral load
has been postulated as a potential prognostic indicator
for FIV infection. A study focusing on disease progression
in SPF cats experimentally infected with two strains of FIV
of different virulence reported a correlation between
disease progression and increased plasma viral load
(Diehl and Hoover, 1995). Similarly, the relationship
between plasma viral load, disease progression and
survival time was found in a study of naturally infected
cats in Japan (Goto et al., 2002). In the present study, the
median FIV load at the time of enrolment from Group 2
was 67-fold higher than that from Group 1 (P < 0.0001)
and there was a marked difference in health status and
mortality rate between groups over the following 22
months. It is not possible to discern whether an increased
viral load was a cause or a consequence of poor health
status, since that would have required knowledge of viral
load kinetics and changes in health status from the time
of initial infection in the FIV-infected ‘healthy’ and ‘not
healthy’ cats; in this prospective study the data were
collected from the time of enrolment. However, statisti-
cally signiﬁcant differences in FIV load between cats from
Group 2 classiﬁed as ‘healthy’ and ‘not healthy’ and cats
that remained alive or died during the study were not
apparent. Observation of these parameters over longer
periods of time, preferably with larger group sizes, would
be required to fully validate their utility in predicting
disease progression.
It has been hypothesized that FIV clade B viruses are
evolutionarily older and more host-adapted, hence less
pathogenic, than those of clade A (Sodora et al., 1994). One
possible explanation for the high morbidity and mortality
in Group 2 is that those cats were infected with highly
virulent strains of FIV. However, this hypothesis was not
supported by the phylogenetic analyses performed, as cats
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 clade B and recombinant A/B viruses. Furthermore,
quences isolated from serial 6-monthly blood collections
monstrated that highly monophyletic groups were
rmed in 96% of the cats from Group 2, suggesting that
ral isolates were not transmitted between cats despite
restricted cohabitation (Be˛czkowski et al., 2014).
though we cannot exclude the possibility that cats from
emphis were infected with more virulent FIV isolates,
sed on thorough phylogenetic analyses of full-length env
quences, this seems unlikely.
A limitation of this study is the restriction of enrol-
ents to two distinct geographic areas; the inclusion of
ts from a wider range of locations could have increased
e variability in virulence of the wild type FIVs examined
d their possible contribution to the onset of disease.
ditionally, for the purposes of this study of naturally
fected cats either adopted from shelters or rescued, it
as necessary to estimate the ages of the cats and to use
e date that the cat ﬁrst tested FIV-positive since the
ecise dates of infection were not known. It has been
ported previously that age at time of ﬁrst exposure to FIV
n inﬂuence the course of infection (George et al., 1993)
d can determine the outcome of disease (Akhtardanesh
 al., 2010). From a biological and behavioural perspective,
e age of approximately 1–2 years old at the time of ﬁrst
agnosis reported in this study is consistent with young
ts engaging in territorial ﬁghts, especially if they are
tire. The cats in our study were originally adopted from
elters and many were entire and had outdoor access at
e time of shelter intake, both known lifestyle risk factors
r FIV (Levy et al., 2006). In our study population, infection
as more common in male cats, conﬁrming the results of
evious studies (Grindem et al., 1989; Hosie et al., 1989;
ida et al., 1989; Levy et al., 2006; Yamamoto et al.,
89). Additionally, FIV status and multi-cat housing
tus could have affected the health of the cats in our
dy; it was not possible to discern whether they acted
dependently or as cofactors. FIV-negative cats matched
 enrolled FIV-positive cats on housing status, as well as
e and sex, were not available during the study enrolment
riod. While an extra layer of matching based on housing
tus would have been ideal, it was not achievable in this
al-world study.
Based on the relatively large number of cats enrolled
d the striking clinical differences observed between the
o cohorts, we conclude that keeping FIV-infected cats in
ercrowded conditions can have a signiﬁcant impact on
e risk of disease progression, particularly in cats which
eady have their immune systems compromised by FIV
fection. In contrast, FIV-positive cats remained in
latively good health when living in stable, single cat
useholds. Clinical signs of disease were not observed at
monthly physical examinations over a 24-month period
 the cats from Group 1 that were housed in single cat
useholds. The average duration of the ‘asymptomatic’
ase of infection remains unknown and could only be
timated following observations over a longer period. In
is study, the selection of study participants from
fferent locations and housing conditions minimized
of this study would have been very different indeed had
efforts been focused on only one of the cohorts presented
herein.
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